A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Latest Information Update: 10 Jul 2024
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Cetuximab; Cisplatin; Fluorouracil
- Indications Head and neck cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms ECHO-304; KEYNOTE-669
- Sponsors Incyte Corporation
- 17 Jan 2024 Planned End Date changed from 27 Dec 2023 to 27 Dec 2024.
- 31 Jul 2023 Planned End Date changed from 23 Jun 2023 to 27 Dec 2023.
- 28 Jul 2022 Planned End Date changed from 27 Jun 2022 to 23 Jun 2023.